View on Pubmed.gov 19861964 | View on doi.org 10.1038/sj.bjc....
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study.
- AstraZeneca Pharmaceuticals, Alderley Park, Cheshire SK10 4TG, UK.
Abstract
BACKGROUND
This study investigated the potential clinical utility of circulating free DNA (cfDNA) as a source of BRAF mutation detection in patients enrolled into a phase II study of AZD6244, a specific MEK1/2 inhibitor, in patients with advanced melanoma.
METHODS
BRAF mutations were detected using Amplification Refractory Mutation System allele-specific PCR. BRAF mutation status was assessed in serum-derived cfDNA from 126 patients enrolled into the study and from 94 matched tumour samples.
RESULTS
Of 94 tumour samples, 45 (47.9%) were found to be BRAF mutation positive (BRAF+). Serum-derived cfDNA was BRAF+ in 33 of 126 (26.2%) samples, including in five samples for which tumour data were unavailable. Of BRAF+ tumours, 25 of 45 (55.6%) were BRAF+ in cfDNA. In three cases in which the tumour was negative, cfDNA was BRAF+. Progression-free survival (PFS) of patients with BRAF+ tumour and cfDNA was not significantly different compared with tumour BRAF+ but cfDNA BRAF-negative patients, indicating that cfDNA BRAF detection is not associated with poorer prognosis on PFS in stage III/IV advanced melanoma.
CONCLUSIONS
These data demonstrate the feasibility of BRAF mutation detection in cfDNA of patients with advanced melanoma. Future studies should aim to incorporate BRAF mutation testing in cfDNA to further validate this biomarker for patient selection.
References
Science. 1994 Aug 12;265(5174):966-70
Int J Cancer. 2007 Jun 1;120(11):2439-44
Nucleic Acids Res. 1989 Apr 11;17(7):2503-16
Nat Med. 2008 Sep;14(9):985-90
Cited by 102 citations (total)
Journal Article
A melanoma molecular disease model.
Electronic publication date July 27, 2011
Smruti J Vidwans [...] Jeff Shrager et al.
While advanced melanoma remains one of the most challenging cancers, recent developments in our understanding of the molecular drivers of...
Journal Article
Current status and future potential of somatic mutation testing from circulating free DNA in patients with solid tumours.
Electronic publication date December 2, 2011
K L Aung [...] C Dive et al.
Genetic alterations can determine the natural history of cancer and its treatment response. With further advances in DNA sequencing technology,...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
- •
- •
- •
- •
Substances
- •
- •
- •
- •
- •